-
Efferocytosis in atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-15 Shaunak S. Adkar, Nicholas J. Leeper
-
Mitral valve prolapse: arrhythmic risk during pregnancy and postpartum Eur. Heart J. (IF 39.3) Pub Date : 2024-05-14 Avi Sabbag, Eivind W Aabel, Anna Isotta Castrini, Konstantinos C Siontis, Mikael Laredo, Jacky Nizard, Guillaume Duthoit, Samuel Asirvatham, Ojasay Sehrawat, Feddo P Kirkels, Philippe J van Rosendael, Roy Beinart, Moshe Rav Acha, Petr Peichl, Han S Lim, Christian Sohns, Raphael Martins, Jonaz Font, Nguyen N K Truong, Mette Estensen, Kristina H Haugaa
Background and Aims Arrhythmic mitral valve prolapse (AMVP) is linked to life-threatening ventricular arrhythmias (VAs), and young women are considered at high risk. Cases of AMVP in women with malignant VA during pregnancy have emerged, but the arrhythmic risk during pregnancy is unknown. The authors aimed to describe features of women with high-risk AMVP who developed malignant VA during the perinatal
-
Periprocedural myocardial infarction after percutaneous coronary intervention and long-term mortality: a meta-analysis Eur. Heart J. (IF 39.3) Pub Date : 2024-05-14 Luca Paolucci, Fabio Mangiacapra, Sara Sergio, Annunziata Nusca, Carlo Briguori, Emanuele Barbato, Gian Paolo Ussia, Francesco Grigioni
Background and Aims Conflicting data are available regarding the association between periprocedural myocardial infarction (PMI) and mortality following percutaneous coronary intervention. The purpose of this study was to evaluate the incidence and prognostic implication of PMI according to the Universal Definition of Myocardial Infarction (UDMI), the Academic Research Consortium (ARC)-2 definition
-
Pushing the limits of natriuresis for poor kidneys in acute heart failure? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Frederik H. Verbrugge
-
Insulin‐like growth factor binding protein‐7 in heart failure: The challenge of moving from risk prediction to a biomarker‐guided management Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Giorgia Panichella, Daniela Tomasoni, Alberto Aimo
-
Letter regarding the article ‘Subclinical systolic dysfunction in genotype‐positive phenotype‐negative relatives of dilated cardiomyopathy patients: A systematic review and meta‐analysis’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Arif Albulushi, Ghalib Al Hinai, Nadya Al Matrooshi
-
Reply to the letter regarding the article ‘Subclinical systolic dysfunction in genotype‐positive phenotype‐negative relatives of dilated cardiomyopathy patients: A systematic review and meta‐analysis’ Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Andrea Faggiano, Elisa Gherbesi, Eleonora Gnan, Alessia Paldino, Marco Merlo, Gianfranco Sinagra, Stefano Carugo
-
What we claim to do and what we really do – a discrepancy in heart failure treatment Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Birgit Assmus, Samuel Sossalla
-
Mitral regurgitation and heart failure with preserved ejection fraction: Should we treat the muscle, the valve, or both? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Mauro Riccardi, Barry A. Borlaug, Riccardo M. Inciardi
-
Frailty according to the 2019 HFA‐ESC definition in patients at risk for advanced heart failure: Insights from the HELP‐HF registry Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Alessandro Villaschi, Mauro Chiarito, Matteo Pagnesi, Davide Stolfo, Luca Baldetti, Carlo Mario Lombardi, Marianna Adamo, Ferdinando Loiacono, Antonio Maria Sammartino, Giada Colombo, Daniela Tomasoni, Riccardo Maria Inciardi, Marta Maccallini, Gaia Gasparini, Marco Montella, Stefano Contessi, Daniele Cocianni, Maria Perotto, Giuseppe Barone, Marco Merlo, Cristiana Vitale, Giuseppe Massimo Claudio
-
Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Muthiah Vaduganathan, Brian L. Claggett, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Akshay S. Desai, Pardeep S. Jhund, Prabhakar Viswanathan, Antonieta Bomfim Wirtz, Patrick Schloemer, James Lay‐Flurrie, John J.V. McMurray, Scott D. Solomon
AimSteroidal mineralocorticoid receptor antagonists (MRAs), spironolactone and eplerenone, are strongly recommended in the treatment of patients with chronic heart failure (HF) with reduced left ventricular ejection fraction (LVEF), but the balance of efficacy and safety in those with higher LVEF has not been well established. Broad use of steroidal MRAs has further been limited in part due to safety
-
404‐error “Disease not found”: Unleashing the translational potential of ‐omics approaches beyond traditional disease classification in heart failure research Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 Antonio Esquivel Gaytan, Nils Bomer, Niels Grote Beverborg, Peter van der Meer
The emergence of personalized medicine, facilitated by the progress in ‐omics technologies, has initiated a new era in medical diagnostics and treatment. This review examines the potential of ‐omics approaches in heart failure, a condition that has not yet fully capitalized on personalized strategies compared to other medical fields like cancer therapy. Here, we argue that integrating multi‐omics technology
-
Measuring congestion with a non‐invasive monitoring device in heart failure and haemodialysis: CONGEST‐HF Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-14 James P. Curtain, Atefeh Talebi, Alasdair McIntosh, Alex McConnachie, Joanne O'Donnell, Paul Welsh, Joanna Osmanska, Matthew M.Y. Lee, Piotr Sonecki, Tony Akl, Joohyun Seo, Venugopal Gopinathan, Jed Hurwitz, Srikanth Thiagarajan, Stephen Pettit, Paul R. Kalra, Rajan K. Patel, Patrick B. Mark, Ninian N. Lang, John J.V. McMurray, Mark C. Petrie, Roy S. Gardner, Pardeep S. Jhund
-
Activated factor X stimulates atrial endothelial cells and tissues to promote remodeling responses through AT1R/NADPH oxidases/SGLT1/2 Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-14 Walaa Fakih, Ali Mroueh, Dal-Seong Gong, Shinnosuke Kikuchi, Michael Paul Pieper, Michel Kindo, Jean-Philippe Mazzucottelli, Arnaud Mommerot, Mohamad Kanso, Patrick Ohlmann, Olivier Morel, Valérie Schini-Kerth, Laurence Jesel
Aims Atrial fibrillation (AF), the most common cardiac arrhythmia favoring ischemic stroke and heart failure involves left atrial remodeling, fibrosis and a complex interplay between cardiovascular risk factors. This study examined whether activated factor X (FXa) induces pro-remodeling and pro-fibrotic responses in atrial endothelial cells (AECs) and human atrial tissues and determined the underlying
-
Harnessing the potential of monocytes/macrophages to regenerate tissue engineered vascular grafts Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-14 Arundhati Das, Randall J Smith, Stelios T Andreadis
Cell-free tissue-engineered vascular grafts provide a promising alternative to treat cardiovascular disease but timely endothelialization is essential for ensuring patency and proper functioning post-implantation. Recent studies from our lab showed that blood cells like monocytes (MCs) and macrophages (Mφ) may contribute directly to cellularization and regeneration of bioengineered arteries in small
-
Inhibition of de novo ceramide synthesis by Sirtuin-1 improves beta-cell function and glucose metabolism in type 2 diabetes Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-13 Srividya Velagapudi, Gergely Karsai, Maria Karsai, Shafeeq A Mohammed, Fabrizio Montecucco, Luca Liberale, Hwan Lee, Federico Carbone, Giovanni Francesco Adami, Kangmin Yang, Margot Crucet, Sokrates Stein, Franceso Paneni, Tetiana Lapikova-Bryhinska, Hyun-Duk Jang, Simon Kraler, Daria Vdovenko, Richard Arnold Züllig, Giovanni G Camici, Hyo-Soo Kim, Reijo Laaksonen, Philipp A Gerber, Thorsten Hornemann
Background Obesity and type 2 diabetes (T2D) are major risk factors for cardiovascular diseases (CVD). Dysregulated pro-apoptotic ceramide synthesis reduces β-cell insulin secretion, thereby promoting hyperglycemic states which may manifest as T2D. Pro-apoptotic ceramides modulate insulin sensitivity and glucose tolerance while being linked to poor cardiovascular outcomes. Sirtuin-1 (SIRT1) is a NAD
-
Renal function and natriuresis‐guided diuretic therapy – a pre‐specified analysis from the PUSH‐AHF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-12 Kevin Damman, Iris E. Beldhuis, Peter van der Meer, Jan A. Krikken, Jenifer E. Coster, Wybe Nieuwland, Dirk J. van Veldhuisen, Adriaan A. Voors, Jozine M. ter Maaten
-
Contemporary guideline‐directed medical therapy in de novo, chronic, and worsening heart failure patients: First data from the TITRATE‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-12 Jishnu Malgie, Mariëlle I. Wilde, Pascal R.D. Clephas, Mireille E. Emans, Stefan Koudstaal, Jeroen Schaap, Arend Mosterd, Jan van Ramshorst, Alexander J. Wardeh, Sandra van Wijk, Mieke van den Heuvel, Eric Wierda, C. Jan Willem Borleffs, Colette Saraber, Saskia L.M.A. Beeres, Roland van Kimmenade, Wouter Jansen Klomp, Robert Denham, Carlos A. da Fonseca, IJsbrand T. Klip, Olivier C. Manintveld, Robert
-
Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials Eur. Heart J. (IF 39.3) Pub Date : 2024-05-11 Sanjiv J Shah, Kavita Sharma, Barry A Borlaug, Javed Butler, Melanie Davies, Dalane W Kitzman, Mark C Petrie, Subodh Verma, Shachi Patel, Khaja M Chinnakondepalli, Mette N Einfeldt, Thomas J Jensen, Søren Rasmussen, Rabea Asleh, Tuvia Ben-Gal, Mikhail N Kosiborod
Background and Aims In the STEP-HFpEF trial program, treatment with semaglutide resulted in multiple beneficial effects in patients with obesity-related heart failure with preserved ejection fraction (HFpEF). Efficacy may vary according to baseline diuretic use, and semaglutide treatment could modify diuretic dose. Methods In this pre-specified analysis of pooled data from the STEP-HFpEF and STEP-HFpEF-DM
-
Identification of three mechanistic pathways for iron-deficient heart failure Eur. Heart J. (IF 39.3) Pub Date : 2024-05-11 Milton Packer, Stefan D Anker, Javed Butler, John G F Cleland, Paul R Kalra, Robert J Mentz, Piotr Ponikowski
Current understanding of iron-deficient heart failure is based on blood tests that are thought to reflect systemic iron stores, but the available evidence suggests greater complexity. The entry and egress of circulating iron is controlled by erythroblasts, which (in severe iron deficiency) will sacrifice erythropoiesis to supply iron to other organs, e.g. the heart. Marked hypoferraemia (typically
-
Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-11 Scott D. Solomon, John W. Ostrominski, Muthiah Vaduganathan, Brian Claggett, Pardeep S. Jhund, Akshay S. Desai, Carolyn S.P. Lam, Bertram Pitt, Michele Senni, Sanjiv J. Shah, Adriaan A. Voors, Faiez Zannad, Imran Zainal Abidin, Marco Antonio Alcocer‐Gamba, John J. Atherton, Johann Bauersachs, Chang‐Sheng Ma, Chern‐En Chiang, Ovidiu Chioncel, Vijay Chopra, Josep Comin‐Colet, Gerasimos Filippatos, Cândida
-
New York Heart Association functional class and implantable cardioverter‐defibrillator in non‐ischaemic heart failure with reduced ejection fraction: Extended follow‐up of the DANISH trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-11 Munise N. Karacan, Seiko N. Doi, Adelina Yafasova, Jens Jakob Thune, Jens C. Nielsen, Jens Haarbo, Niels E. Bruun, Finn Gustafsson, Hans Eiskjær, Christian Hassager, Jesper H. Svendsen, Dan E. Høfsten, Steen Pehrson, Lars Køber, Jawad H. Butt
-
Sacubitril/valsartan and cardiovascular biomarkers among patients with recent COVID‐19 infection: The PARACOR‐19 randomized clinical trial Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-11 Stephen J. Greene, RaKavius Chambers, Joseph B. Lerman, Josephine Harrington, Christopher R deFilippi, David C. Wendell, Han W. Kim, Cynthia L. Green, Javed Butler, G. Michael Felker
AimsThe PARACOR‐19 randomized controlled trial (RCT) was designed to examine the effects of sacubitril/valsartan on markers of cardiac injury, inflammation, structure, and function among patients who have recovered from acute coronavirus disease 2019 (COVID‐19) infection.Methods and resultsPARACOR‐19 was a single‐centre, double‐blind RCT of patients with cardiovascular risk factors and a history of
-
Connexin 43 modulates reverse electron transfer in cardiac mitochondria from inducible knock-out Cx43Cre−ER(T)/fl mice by altering the coenzyme Q pool Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-05-09 Marta Consegal, Elisabet Miró-Casas, Ignasi Barba, Marisol Ruiz-Meana, Javier Inserte, Begoña Benito, Cristina Rodríguez, Freddy G. Ganse, Laura Rubio-Unguetti, Carmen Llorens-Cebrià, Ignacio Ferreira-González, Antonio Rodríguez-Sinovas
-
The role and mechanism of epigenetics in anticancer drug-induced cardiotoxicity Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-05-09 Xuening Liu, Zijian Li
-
Improvements in quality of heart failure randomized controlled trials: Progress and persisting challenges! Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Amr Abdin, Saarraaken Kulenthiran
-
Critical re‐evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Milton Packer, Stefan D. Anker, Javed Butler, John G.F. Cleland, Paul R. Kalra, Robert J. Mentz, Piotr Ponikowski, Khawaja M. Talha
According to current guidelines, iron deficiency is defined by a serum ferritin level <100 ng/ml or a transferrin saturation (TSAT) <20% if the serum ferritin level is 100–299 μg/L. These criteria were developed to encourage the use of intravenous iron as an adjunct to erythropoiesis‐stimulating agents in the treatment of renal anaemia. However, in patients with heart failure, these criteria are not
-
Impact of heart failure hospitalizations on clinical outcomes after mitral transcatheter edge‐to‐edge repair: Results from the EXPAND study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Mirjam Kessler, Wolfgang Rottbauer, Ralph Stephan von Bardeleben, Carmelo Grasso, Philipp Lurz, Paul Mahoney, Matthew Price, Mathew Williams, Paolo Denti, Rodrigo Estevez‐Loureiro, Saibal Kar, Francesco Maisano
-
Iron homeostasis, recycling and vulnerability in the stressed kidney: A neglected dimension of iron‐deficient heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-10 Milton Packer
The available evidence suggests that the kidney may contribute importantly to the development of an iron deficiency state in patients with heart failure and may be injured by therapeutic efforts to achieve iron repletion. The exceptional workload of the proximal renal tubule requires substantial quantities of iron for ATP synthesis, which it derives from Fe3+ bound to transferrin in the bloodstream
-
Empagliflozin inhibits increased Na influx in atrial cardiomyocytes of patients with HFpEF Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-10 M Trum, J Riechel, E Schollmeier, S Lebek, P Hegner, K Reuthner, S Heers, K Keller, M Wester, S Klatt, N Hamdani, Z Provaznik, C Schmid, L S Maier, M Arzt, S Wagner
Aims Heart failure with preserved ejection fraction (HFpEF) causes substantial morbidity and mortality. Importantly, atrial remodeling and atrial fibrillation is frequently observed in HFpEF. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have recently been shown to improve clinical outcomes in HFpEF, and post-hoc analyses suggest atrial antiarrhythmic effects. We tested if isolated human atrial
-
Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial Eur. Heart J. (IF 39.3) Pub Date : 2024-05-09 P R D Clephas, V W Zwartkruis, J Malgie, M W F van Gent, H P Brunner-La Rocca, M K Szymanski, V P van Halm, M L Handoko, W Kok, F W Asselbergs, R van Kimmenade, O Manintveld, N M D A van Mieghem, S L M A Beeres, M C Post, C J W Borleffs, R Tukkie, A Mosterd, G C M Linssen, R F Spee, M E Emans, T D J Smilde, J van Ramshorst, C Kirchhof, F Feenema–Aardema, C A da Fonseca, M van den Heuve, R Hazeleger
Background and Aims In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated the efficacy of pulmonary artery (PA)-guided HF therapy over standard of care in improving quality of life and reducing HF hospitalizations and mean PA pressure. This study aimed to evaluate the consistency of these benefits in relation to clinically relevant subgroups. Methods The effect of PA-guided
-
Reduced congestion and improved response to a fluid/sodium challenge in chronic heart failure patients after initiation of sacubitril/valsartan: The NATRIUM‐HF study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-09 Alexandre Mebazaa, Beth A. Davison, Jan Biegus, Christopher Edwards, Gillian Murtagh, Christos Varounis, Hamlet Hayrapetyan, Hamayak Sisakian, Victor R. Ter‐Grigoryan, Koji Takagi, Maria Novosadova, Piotr Ponikowski, Gad Cotter
AimsThe effects of initiating sacubitril/valsartan in patients with stable heart failure with reduced ejection fraction (HFrEF) on response to fluid and sodium expansion are unknown.Methods and resultsWe have explored changes in natriuresis, diuresis, and congestion in response to the administration of intravenous fluid/sodium load in patients with HFrEF before as compared to after the initiation of
-
Inhibition of TBL1 cleavage alleviates doxorubicin-induced cardiomyocytes death by regulating the Wnt/β-catenin signal pathway Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-09 Sun-Ho Lee, Jangho Lee, Jaewon Oh, Jin-Taek Hwang, Hae-Jeung Lee, Hwa Kyung Byun, Hyeong-Jin Kim, David Suh, Ho-Geun Yoon, Sahng Wook Park, Seok-Min Kang, Chulan Kwon, Seung-Hyun Lee, Hyo-Kyoung Choi
Aims Doxorubicin (DOX) is a widely used anthracycline anticancer agent; however, its irreversible effects on the heart can result in DOX-induced cardiotoxicity (DICT) after cancer treatment. Unfortunately, the pathophysiology of DICT has not yet been fully elucidated, and there are no effective strategies for its prevention or treatment. In this investigation, the novel role of transducin beta-like
-
Role of endothelial Raptor in abnormal arteriogenesis after lower limb ischemia in type-2 diabetes Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-09 Ting Liu, Jiachen Zhang, Fangyuan Chang, Mengyu Sun, Jinlong He, Ding Ai
Aims Proper arteriogenesis after tissue ischemia is necessary to rebuild stable blood circulation; nevertheless, this process is impaired in type-2 diabetes mellitus (T2DM). Raptor, is a scaffold protein and a component of mammalian target of rapamycin complex 1 (mTORC1). However, the role of the endothelial Raptor in arteriogenesis under the conditions of T2DM remains unknown. This study investigated
-
Adenosine kinase inhibition protects mice from abdominal aortic aneurysm via epigenetic modulation of VSMC inflammation Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-09 Jiean Xu, Zhiping Liu, Qiuhua Yang, Qian Ma, Yaqi Zhou, Yongfeng Cai, Dingwei Zhao, Guizhen Zhao, Tammy Lu, Kunfu Ouyang, Mei Hong, Ha Won Kim, Huidong Shi, Jifeng Zhang, David Fulton, Clint Miller, Rajeev Malhotra, Neal L Weintraub, Yuqing Huo
Aim Abdominal aortic aneurysm (AAA) is a common, serious vascular disease with no effective pharmacological treatment. The nucleoside adenosine plays an important role in modulating vascular homeostasis, which prompted us to determine whether adenosine kinase (ADK), an adenosine metabolizing enzyme, modulates AAA formation via control of intracellular adenosine level, and to investigate the underlying
-
Unveiling cellular and molecular aspects of ascending thoracic aortic aneurysms and dissections Basic Res. Cardiol. (IF 9.5) Pub Date : 2024-05-03 Berta H. Ganizada, Rogier J. A. Veltrop, Asim C. Akbulut, Rory R. Koenen, Ryan Accord, Roberto Lorusso, Jos G. Maessen, Koen Reesink, Elham Bidar, Leon J. Schurgers
-
Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and High Bleeding Risk JAMA Cardiol. (IF 24.0) Pub Date : 2024-05-08 Andrea Erriquez, Gianluca Campo, Vincenzo Guiducci, Javier Escaned, Raul Moreno, Gianni Casella, Mila Menozzi, Enrico Cerrato, Giorgio Sacchetta, Alberto Menozzi, Ignacio Amat Santos, Enrique Gutiérrez Ibañes, Roberto Scarsini, Giuseppe Vadalà, Giuseppe Andò, José Luis Díez-Gil, Sergio Musto d’Amore, Alessandro Capecchi, Iginio Colaiori, Francesco Gallo, Rita Pavasini, Andrea Marrone, Graziella Pompei
ImportancePatients with high bleeding risk (HBR) have a poor prognosis, and it is not known if they may benefit from complete revascularization after myocardial infarction (MI).ObjectiveTo investigate the benefit of physiology-guided complete revascularization vs a culprit-only strategy in patients with HBR, MI, and multivessel disease.Design, Setting, and ParticipantsThis was a prespecified analysis
-
Underrepresentation of Women in Revascularization Trials JAMA Cardiol. (IF 24.0) Pub Date : 2024-05-08 Celina M. Yong, William F. Fearon
This Viewpoint discusses the unequal representation of women in coronary revascularization trials in the US, its negative effects on the cardiovascular health of both sexes, and potential mechanisms to ensure appropriate representation of women moving forward.
-
Guideline‐directed medical therapy in patients with heart failure with preserved ejection fraction and polypharmacy: Do not be afraid Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-08 Husam M. Salah, Marat Fudim
-
Metabolomics to predict heart failure development: A new frontier? Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-08 Giorgia Panichella, Daniela Tomasoni, Alberto Aimo
-
Echocardiographic predictors of cardiovascular outcome in heart failure with preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-08 Nelson Wang, Phidias Rueter, Melvin Ng, Sashiruben Chandramohan, Thomas Hibbert, John F. O'Sullivan, David Kaye, Sean Lal
AimsThe optimal echocardiographic predictors of cardiovascular outcome in heart failure (HF) with preserved ejection fraction (HFpEF) are unknown. We aimed to identify independent echocardiographic predictors of cardiovascular outcome in patients with HFpEF.Methods and resultsSystematic literature search of three electronic databases was conducted from date of inception until November 2022. Hazard
-
Illusion of revascularization: does anyone achieve optimal revascularization during percutaneous coronary intervention? Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-07 Simone Fezzi, Daixin Ding, Felix Mahfoud, Jiayue Huang, Alexandra J. Lansky, Shengxian Tu, William Wijns
-
Correction to “Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction” Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-07
Chandramouli C, Ting TW, Tromp J, Agarwal A, Svedlund S, Saraste A, et al. Sex differences in proteomic correlates of coronary microvascular dysfunction among patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2022;24:681–684. https://doi.org/10.1002/ejhf.2435 Within the abstract, in the Methods and Results section (2nd last line) P13K is incorrect (typo), it should read
-
Evaluation of the Hemocompatibility of the Direct Oral Anticoagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study JACC Heart Fail. (IF 13.0) Pub Date : 2024-05-07 Palak Shah MD MS, Mary Looby PharmD, Matthew Dimond BS, Pramita Bagchi PhD, Bhruga Shah MS BSN-RN, Iyad Isseh MD, Allman T. Rollins MD, Ahmad A. Abdul-Aziz MD, Jamie Kennedy MD, Daniel G. Tang MD, Katherine M. Klein MD, Samantha Casselman MSN RN, Christen Vermeulen MSN RN, Wendy Sheaffer BSN RN, Meredith Snipes BSN RN, Shashank S. Sinha MD MS, Christopher M. O’Connor MD
-
FLT4 causes developmental disorders of the cardiovascular and lymphovascular systems via pleiotropic molecular mechanisms Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-07 Richard M Monaghan, Richard W Naylor, Daisy Flatman, Paul R Kasher, Simon G Williams, Bernard D Keavney
Aims Rare, deleterious genetic variants in FLT4 are associated with Tetralogy of Fallot (TOF), the most common cyanotic congenital heart disease (CHD). Distinct genetic variants in FLT4 are also an established cause of Milroy disease, the most prevalent form of primary hereditary lymphoedema. Phenotypic features of these two conditions are non-overlapping, implying pleiotropic cellular mechanisms during
-
Spatiotemporal ATF3 Expression Determines VSMC Fate in Abdominal Aortic Aneurysm Circ. Res. (IF 20.1) Pub Date : 2024-04-30 Ying Wen, Yingying Liu, Qiang Li, Jinlin Tan, Xing Fu, Yiwen Liang, Yonghua Tuo, Luhao Liu, Xueqiong Zhou, Dongkai LiuFu, Xuejiao Fan, Chaofei Chen, Zheng Chen, Zhouping Wang, Shunyang Fan, Renjing Liu, Lei Pan, Yuan Zhang, Wai Ho Tang
BACKGROUND:Abdominal aortic aneurysm (AAA) is a catastrophic disease with little effective therapy, likely due to the limited understanding of the mechanisms underlying AAA development and progression. Activating transcription factor (ATF) 3 has been increasingly recognized as a key regulator of cardiovascular diseases. However, the role of ATF3 (activating transcription factor 3) in AAA development
-
Ertugliflozin for Functional Mitral Regurgitation Associated With Heart Failure: EFFORT Trial Circulation (IF 37.8) Pub Date : 2024-05-01 Duk-Hyun Kang, Sung-Ji Park, Sung-Hee Shin, In-Chang Hwang, Yeonyee Elizabeth Yoon, Hyung-Kwan Kim, Mijin Kim, Min-Seok Kim, Sung-Cheol Yun, Jong-Min Song, Seok-Min Kang
BACKGROUND:The morbidity and mortality rates of patients with heart failure (HF) and functional mitral regurgitation (MR) remain substantial despite guideline-directed medical therapy for HF. We evaluated the efficacy of ertugliflozin for reduction of functional MR associated with HF with mild to moderately reduced ejection fraction.METHODS:The EFFORT trial (Ertugliflozin for Functional Mitral Regurgitation)
-
Atherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like Disease Circulation (IF 37.8) Pub Date : 2024-04-30 Huize Pan, Sebastian E. Ho, Chenyi Xue, Jian Cui, Quinian S. Johanson, Nadja Sachs, Leila S. Ross, Fang Li, Robert A. Solomon, E. Sander Connolly Jr, Virendra I. Patel, Lars Maegdefessel, Hanrui Zhang, Muredach P. Reilly
BACKGROUND:Atherosclerosis, a leading cause of cardiovascular disease, involves the pathological activation of various cell types, including immunocytes (eg, macrophages and T cells), smooth muscle cells (SMCs), and endothelial cells. Accumulating evidence suggests that transition of SMCs to other cell types, known as phenotypic switching, plays a central role in atherosclerosis development and complications
-
PDZ-Binding Kinase, a Novel Regulator of Vascular Remodeling in Pulmonary Arterial Hypertension Circulation (IF 37.8) Pub Date : 2024-04-29 Zsuzsanna Bordan, Robert Batori, Stephen Haigh, Xueyi Li, Mary Louise Meadows, Zach L. Brown, Madison A. West, Kunzhe Dong, Weihong Han, Yunchao Su, Qian Ma, Yuqing Huo, Jiliang Zhou, Mahmoud Abdelbary, Jennifer Sullivan, Neal. L. Weintraub, David W. Stepp, Feng Chen, Scott A. Barman, David J.R. Fulton
BACKGROUND:Pulmonary arterial hypertension (PAH) is high blood pressure in the lungs that originates from structural changes in small resistance arteries. A defining feature of PAH is the inappropriate remodeling of pulmonary arteries (PA) leading to right ventricle failure and death. Although treatment of PAH has improved, the long-term prognosis for patients remains poor, and more effective targets
-
miR-369-3p ameliorates diabetes-associated atherosclerosis by regulating macrophage succinate-GPR91 signaling Cardiovasc. Res. (IF 10.8) Pub Date : 2024-05-04 Shruti Rawal, Vinay Randhawa, Syed Husain Mustafa Rizvi, Madhur Sachan, Akm Khyrul Wara, Daniel Pérez-Cremades, Robert M Weisbrod, Naomi M Hamburg, Mark W Feinberg
Aims Diabetes leads to dysregulated macrophage immunometabolism, contributing to accelerated atherosclerosis progression. Identifying critical factors to restore metabolic alterations and promote resolution of inflammation remains an unmet goal. MicroRNAs (miRs) orchestrate multiple signaling events in macrophages, yet their therapeutic potential in diabetes-associated atherosclerosis remains unclear
-
No benefit of apoA-I infusion after myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-03 Gregory B. Lim
In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.
-
Adult Congenital Heart Disease Circulation (IF 37.8) Pub Date : 2024-04-29 Mikael Dellborg
Congenital heart disease (CHD) is a field of cardiology where perhaps the most dramatic evolution has occurred over the last 40 to 50 years. The stunning development of antenatal diagnostics, interventional catheterization, cardiothoracic surgery, echocardiography, and pre- and postoperative intensive care as well as important pharmacological advances have improved prognosis during childhood. While
-
Under pressure: Advances in device‐based heart failure therapy for patients with preserved or mildly reduced ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Lukas Stolz, Jörg Hausleiter
-
Is it worth tying the knot? The lifelong commitment between heart failure patients and pulmonary artery pressure monitoring Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Emil Wolsk
-
Identification and outcomes of KDIGO‐defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Samir S. Patel, Venkatesh K. Raman, Sijian Zhang, Prakash Deedwania, Qing Zeng‐Treitler, Wen‐Chih Wu, Phillip H. Lam, George Bakris, Hans Moore, Paul A. Heidenreich, Janani Rangaswami, Charity J. Morgan, Yan Cheng, Helen M. Sheriff, Charles Faselis, Ravindra L. Mehta, Stefan D. Anker, Gregg C. Fonarow, Ali Ahmed
-
Tailored immunosuppression in biopsy‐proven immune‐mediated myocarditis Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Petr Kuchynka, Jan Krejci, Tomas Palecek
-
Dapagliflozin and quality of life measured using the EuroQol 5‐dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Mingming Yang, Toru Kondo, Atefeh Talebi, Pardeep S. Jhund, Kieran F. Docherty, Brian L. Claggett, Muthiah Vaduganathan, Erasmus Bachus, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Mikhail N. Kosiborod, Akshay S. Desai, Lars Køber, Piotr Ponikowski, Marc S. Sabatine, Scott D. Solomon, John J.V. McMurray
-
Use of medical therapy and risk of clinical events according to frailty in heart failure patients – A real‐life cohort study Eur. J. Heart Fail. (IF 18.2) Pub Date : 2024-05-03 Deewa Zahir Anjum, Jarl E. Strange, Emil Fosbøl, Caroline Hartwell Garred, Mariam Elmegaard, Charlotte Andersson, Pardeep S. Jhund, John J.V. McMurray, Mark C. Petrie, Lars Kober, Morten Schou
AimsAlthough recent randomized clinical trials have demonstrated the advantages of heart failure (HF) therapy in both frail and not frail patients, there is insufficient information on the use of HF therapy based on frailty status in a real‐world setting. The aim was to examine how frailty status in HF patients associates with use of HF therapy and with clinical outcomes.Methods and resultsPatients
-
Stress and cardiovascular disease: an update Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-05-02 Viola Vaccarino, J. Douglas Bremner
-
Lower extremity arterial disease vs. coronary artery disease: mortality differences after revascularization Eur. Heart J. (IF 39.3) Pub Date : 2024-05-02 Mitsuyoshi Takahara, Yoshimitsu Soga, Osamu Iida
Background and Aims Patients undergoing revascularization for lower extremity arterial disease (LEAD) may face a higher risk of mortality than those with coronary artery disease (CAD). This study aimed to characterize the difference in mortality risk between patients undergoing revascularization for LEAD and CAD and identify associated factors. Methods The 1-year database of 10 754 patients undergoing